Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

38.40 -0.25 (-0.66%)
Streaming Delayed Price Updated: 3:30 PM EDT, Jun 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,431,105
Open 38.81
Bid (Size) 38.39 (40)
Ask (Size) 38.40 (46)
Prev. Close 38.65
Today's Range 38.29 - 38.86
52wk Range 36.17 - 54.93
Shares Outstanding 5,606,688,356
Dividend Yield 4.06%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Pharmaceutical Giant Merck Challenges Inflation Reduction Act over Medicare Drug Pricing, Calls It 'Extortion'
Merck & Co Inc (NYSE: MRK) has reportedly filed a lawsuit against the U.S. government to halt implementing the Medicare drug price negotiation program outlined in the Inflation Reduction Act (IRA).  
Via Benzinga
This Is What Whales Are Betting On Pfizer
 
Via Benzinga

Performance

YTD
-25.10%
-25.10%
1 Month
-0.71%
-0.71%
3 Month
-6.60%
-6.60%
6 Month
-24.31%
-24.31%
1 Year
-27.91%
-27.91%

More News

Read More
Veterinary Healthcare Product Market to See Huge Growth : Pfizer, Merck, Johnson & Johnson
Via SBWire
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Why Pfizer Stock Is Perking Up Today
Via The Motley Fool
SEC Accuses Binance & Coinbase Of Acting As Unregistered Broker, Binance Takes Biggest Hit As $300M In Crypto Positions Liquidated In 24 Hours, JPMorgan Clarifies CEO Jamie Dimon Not Running For Presidency: Today's Top Stories
Via Benzinga
Novavax's New Vaccine Approach Set to Tackle Rising COVID-19 Emerging Variants
Via Benzinga
3 Biotech Stocks to Sell in June Before They Crash and Burn
Via InvestorPlace
Could Pfizer Have an Ozempic Killer on the Way?
Via The Motley Fool
Looking for Passive Income at a Decent Price? Buy These 2 Stocks
Via The Motley Fool
Here Are All The Corporate CEOs Who Made A Beeline To China To Chase Huge Market Opportunities Amid The Country's Reopening
Via Benzinga
3 Dividend Stocks You Can Buy Without Any Hesitation
Via The Motley Fool
Why Shares of BioNTech Rose Friday
Via The Motley Fool
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Via Investor's Business Daily
BioNTech Surges On This Promising Update In Its Bid To Take On Bristol Myers In Lung Cancer Treatment
Via Investor's Business Daily
3 Undervalued Biotech Stocks to Buy Before They Blast Off
Via InvestorPlace
7 Deeply Undervalued Growth Stocks to Buy in June
Via InvestorPlace
AI, Tech Fuel Rebound Of Vanguard Growth ETF, Eroding Value's 2022 Outperformance
Via Benzinga
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
Via Investor's Business Daily
Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
From Pfizer Inc.
Via Business Wire
Is CXApp Inc.an AI Contender or Pretender?
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Have $2,000? 2 Remarkable Growth Stocks to Buy Right Now
Via The Motley Fool
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
From Pfizer Inc.
Via Business Wire
This Cannabis-Based Drug Has Outperformed Pfizer's Lyrica In Clinical Trials: A New Dawn For Diabetic Nerve Pain Management?
Via Benzinga
Most Active Equity Options For Midday - Wednesday, May 31
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.